Drug Profile
Research programme: protease-activated receptor-2 inhibitor - NeoPharm
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator NeoPharm Co
- Class Skin disorder therapies
- Mechanism of Action PAR 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Skin disorders
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Skin-disorders in South Korea
- 14 Jul 2016 Early research is ongoing in South Korea